OUP accepted manuscript

Apetrii, Mugurel; Enache, Stefana; Siriopol, Dimitrie; Burlacu, Alexandru; Kanbay, Asiye; Kanbay, Mehmet; Scripcariu, Dragoş Viorel; Covic, Adrian

doi:10.1093/ckj/sfaa082

Cited by 20 publications

(5 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients presenting with sepsis have multiorgan dysfunction over 50% of the time, especially involving cardiac and renal function, explaining the high mortality involved. [ 122 ] We observed this during the COVID-19 pandemic with systemic vascular inflammation [ 123 , 124 , 125 , 126 , 127 ].…”

Section: Cardiorenal Syndrome: a Definitionmentioning

confidence: 99%

OX-HDL: A Starring Role in Cardiorenal Syndrome and the Effects of Heme Oxygenase-1 Intervention

et al. 2020

View full text Add to dashboard Cite

In this review, we will evaluate how high-density lipoprotein (HDL) and the reverse cholesterol transport (RCT) pathway are critical for proper cardiovascular–renal physiology. We will begin by reviewing the basic concepts of HDL cholesterol synthesis and pathway regulation, followed by cardiorenal syndrome (CRS) pathophysiology. After explaining how the HDL and RCT pathways become dysfunctional through oxidative processes, we will elaborate on the potential role of HDL dysfunction in CRS. We will then present findings on how HDL function and the inducible antioxidant gene heme oxygenase-1 (HO-1) are interconnected and how induction of HO-1 is protective against HDL dysfunction and important for the proper functioning of the cardiovascular–renal system. This will substantiate the proposal of HO-1 as a novel therapeutic target to prevent HDL dysfunction and, consequently, cardiovascular disease, renal dysfunction, and the onset of CRS.

show abstract

Section: Cardiorenal Syndrome: a Definitionmentioning

confidence: 99%

OX-HDL: A Starring Role in Cardiorenal Syndrome and the Effects of Heme Oxygenase-1 Intervention

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Coronavirus disease 2019 (COVID-19), a viral illness affecting multiple organs including the kidneys, has led to high morbidity and mortality [ 1 , 2 ]. Several reports indicate that the presence of acute kidney injury (AKI) in COVID-19 patients contributes to the poor prognosis [ 3 , 4 ]. The incidence of AKI in patients hospitalized for COVID-19 varies widely, with some studies reporting an incidence ranging from 0.5% to as high as 46% [ 3 , 5 , 6 ].…”

Section: Introductionmentioning

confidence: 99%

Acute kidney injury in hospitalized COVID-19 patients

Kanbay

Medetalibeyoğlu

Kanbay³

et al. 2021

Int Urol Nephrol

View full text Add to dashboard Cite

Background Acute kidney injury (AKI) in COVID-19 patients is associated with poor prognosis. However, the incidence, risk factors and potential outcomes of AKI in hospitalized patients are not well studied. Materials and methods This is a retrospective cohort study conducted in two major university hospitals. Electronic health records of the patients, 18 years or older, hospitalized between 13 April and 1 June 2020 with confirmed COVID-19 were reviewed. We described the incidence and the risk factors for AKI development in COVID-19 patients. Furthermore, we investigated the effects of AKI on the length of hospital and intensive care unit (ICU) stay, the admission rates to ICU, the percentage of patients with cytokine storm and in-hospital mortality rate. Results Among 770 hospitalized patients included in this study, 92 (11.9%) patients developed AKI. The length of hospitalized days (16 vs 9.9, p < 0.001) and days spent in the hospital until ICU admission (3.5 vs. 2.5, p = 0.003) were higher in the AKI group compared to patients without AKI. In addition, ICU admission rates were also significantly higher in patients with AKI (63% vs. 20.7%, p < 0.001). The percentage of patients with AKI who developed cytokine storm was significantly higher than patients without AKI (25.9% vs. 14%, p = 0.009). Furthermore, the in-hospital mortality rate was significantly higher in patients with AKI (47.2% vs. 4.7%, p < 0.001). Conclusions AKI is common in hospitalized COVID-19 patients. Furthermore, we show that AKI increases the admission rates to ICU and in-hospital mortality. Our findings suggest that AKI should be effectively managed to prevent the adverse outcomes in COVID-19 patients.

show abstract

“… 10 Various studies have documented cardiac involvement in COVID-19 with complications like myocarditis, 11 acute myocardial infarction 12 and exacerbation of heart failure. 1 13 14 The kidneys are affected as sequelae of direct cellular injury, 15 sepsis or cytokine storm in COVID-19. Previous studies of severe acute respiratory syndrome and Middle East respiratory syndrome-associated coronaviruses showed a prevalence of acute renal insult (AKI) of 5%–15%.…”

Section: Discussionmentioning

confidence: 99%

Cardiorenal syndrome in COVID-19

2021

View full text Add to dashboard Cite

SARS-CoV-2 preferentially targets the human’s lungs, but it can affect multiple organ systems. We report a case of cardiorenal syndrome in a 37-year-old man who had symptoms of fever, myalgia and cough. He tested positive for COVID-19 and presented 5 days later with acute heart failure. Work up was done including echocardiography showing reduced ejection fraction. Later in the hospital course he developed acute renal failure and was treated with intermittent renal replacement therapy. No other definite cause of cardiorenal complications was identified during the course of the disease. A possible link with COVID-19 was considered with underlying mechanisms still needed to be explored. This case highlights the potential of SARS-CoV-2 affecting heart and kidneys. The disease not only involves the organs directly but can exacerbate the underlying comorbid illness.

show abstract

OUP accepted manuscript

Cited by 20 publications

References 49 publications

OX-HDL: A Starring Role in Cardiorenal Syndrome and the Effects of Heme Oxygenase-1 Intervention

OX-HDL: A Starring Role in Cardiorenal Syndrome and the Effects of Heme Oxygenase-1 Intervention

Acute kidney injury in hospitalized COVID-19 patients

Cardiorenal syndrome in COVID-19

Contact Info

Product

Resources

About